Of note, AKR1B10, ACSL4, GLS2, LCAT, were among the metabolic targets we previously identified as consistent in HCC [13], indicating a high alteration frequency of these genes across liver cancer datasets. This evidence concerns the gene GLS2 and hepatocellular carcinoma.